Royalty Pharma (RPRX) Stock Statistics & Valuation Metrics

Royalty Pharma has a market cap or net worth of $38.94B. The enterprise value is $43.51B.

Market Cap

$38.94B

Enterprise Value

$43.51B

Royalty Pharma has 446,619,200 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding

446,619,200

Owned by Insiders

1.46%

Owned by Institutions

39.12%

Royalty Pharma’s return on equity (ROE) is 0.12 and return on invested capital (ROIC) is 8.95%.

Return on Equity (ROE)

0.12

Return on Assets (ROA)

0.04

Return on Invested Capital (ROIC)

8.95%

Return on Capital Employed (ROCE)

0.08

Revenue Per Employee

23.78M

Profits Per Employee

7.71M

Employee Count

100

Asset Turnover

0.12

Inventory Turnover

0.00

The current PE Ratio of Royalty Pharma is 39.97. Royalty Pharma’s PEG ratio is -1.84.

PE Ratio

39.97

PS Ratio

11.50

PB Ratio

4.40

Price to FCF

10.17

Price to Operating Cash Flow

10.16

PEG Ratio

-1.84

In the last 12 months, Royalty Pharma had revenue of 2.38B and earned 770.95M in profits. Earnings per share was 2.33.

Revenue

2.38B

Gross Profit

2.38B

Operating Income

1.56B

Pretax Income

1.32B

Net Income

770.95M

EBITDA

1.64B

Earnings Per Share (EPS)

2.33

In the last 12 months, operating cash flow was 2.96B and capital expenditures 0, giving a free cash flow of 2.96B billion.

Operating Cash Flow

2.96B

Free Cash Flow

2.96B

Free Cash Flow per Share

6.65

Royalty Pharma pays an annual dividend of $0.24, resulting in a dividend yield of 1.37%

Dividend Per Share

$0.24

Dividend Yield

1.37%

Payout Ratio

17.93%

Free Cash Flow Yield

9.83%

Earnings Yield

2.23%

Beta

0.12

52-Week Price Change

67.17%

50-Day Moving Average

60.52

200-Day Moving Average

53.66

Relative Strength Index (RSI)

74.45

Average Volume (3m)

3.12M

Royalty Pharma upcoming earnings date is Feb 16, 2027, TBA (Not Confirmed).

Last Earnings Date

Nov 04, 2026

Next Earnings Date

Feb 16, 2027

Ex-Dividend Date

Aug 14, 2026

Royalty Pharma as a current ratio of 0.97, with Debt / Equity ratio of 138.20%

Current Ratio

0.97

Quick Ratio

0.97

Debt to Market Cap

0.54

Net Debt to EBITDA

5.09

Interest Coverage Ratio

5.07

In the past 12 months, Royalty Pharma has paid 0 in taxes.

Income Tax

0

Effective Tax Rate

0.00

Royalty Pharma EV to EBITDA ratio is 24.67, with an EV/FCF ratio of 12.90.

EV to Sales

14.59

EV to EBITDA

24.67

EV to Free Cash Flow

12.90

EV to Operating Cash Flow

12.90

Royalty Pharma has $544.86M in cash and marketable securities with $8.59B in debt, giving a net cash position of -$8.04B billion.

Cash & Marketable Securities

$544.86M

Total Debt

$8.59B

Net Cash

-$8.04B

Net Cash Per Share

-$18.01

Tangible Book Value Per Share

$19.93

Gross margin is 87.34%, with operating margin of 59.80%, and net profit margin of 25.68%.

Gross Margin

87.34%

Operating Margin

59.80%

Pretax Margin

44.81%

Net Profit Margin

25.68%

EBITDA Margin

59.15%

EBIT Margin

59.01%

The average price target for Royalty Pharma is $70.67, which is 11.43% higher than the current price. The consensus rating is Strong Buy

Price Target

$70.67

Price Target Upside

4.58% Upside

Analyst Consensus

Strong Buy

Analyst Count

6

Revenue Growth Forecast

11.34%

EPS Growth Forecast

-12.26%

Smart Score

10

AI Score

72